Ann: Positive new DMD Combination Therapy Data in mdx mice, page-26

Exciting results - strengthening the ANP patents on combo therapy with Exon skipping drugs...and the necessary nerdy data to get Sarepta's attention.

Given our PI for the P2B trial is Dr Voit - who is one of the inventors of Micro-dystrophin IP used by Sarepta, maybe the lines of communication are finally open?

No dystrophin, just increase in muscle and reduced inflammation - with a 33% increase in the MyoM1 protein...and modulation of BTLA and FABP4.

Just need the money tox study to drop end of year, and the US door opens a little more.
.